FDA Clearance Tracker · K242109
Xpert® Xpress CoV-2 plus (XPRS-COV2-10)
Last checked: Nov 20, 2026Latest source record: Jan 15, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Jan 15, 2025
Substantially Equivalent
Time to decision
180 days
Received Jul 19, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Dual Track
Device class
Class II
The decision
- FDA number
- K242109
- Device name
- Xpert® Xpress CoV-2 plus (XPRS-COV2-10)
- Applicant
- Cepheid®
- Applicant location
- Sunnyvale, CA
- Received
- Jul 19, 2024
- Decided
- Jan 15, 2025
- Decision
- Substantially Equivalent
- Submission type
- Dual Track
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3981
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code QQX. The earliest in FDA's data is K211079, decided Nov 1, 2021.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K242109
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Cepheid®
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K262971 · Decided Oct 30, 2026 · 65 days after receipt
Device type: Multiplex Nucleic Acid Detection System For Biothreat Agents (QVR) · Laboratory Medicine & Pathology
K263333 · Decided Oct 22, 2026 · 30 days after receipt
Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF) · Laboratory Medicine & Pathology
K263120 · Decided Oct 2, 2026 · 28 days after receipt
Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.